Protocol ID

Trial Title

SCRI UNKPRI 15, AVF 2968s; NCT00193622

A Phase II Clinical Trial of Bevacizumab and Erlotinib in Patients With Metastatic Carcinoma of Unknown Primary Site

SCRI GU 22; AVF3120S; CST1571 BUS182; NCT00193258

A Phase I/II Trial of Bevacizumab (Avastin), Erlotinib (Tarceva), and Imatinib (Gleevec) in the Treatment of Patients with Advanced Renal Cell Carcinoma

CRAD001C2242; NCT00478634

An Open Label, Multicenter Phase I Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second Line Therapy After FOLFOX (or XELOX) Plus Bevacizumab (if Given as Part of Local Standard Practice) in Patients With Metastatic Colorectal Adenocarcinoma

SOLTI0701; SOLTI-0701; EudraCT 2007-000290-32

AVF3671g; NCT00257608

A Randomized, Double-Blind, Placebo-Controlled, Phase IIIb Trial Comparing Bevacizumab Therapy With or Without Erlotinib After Completion of Chemotherapy With Bevacizumab for the First Line Treatment of Locally Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer

MO16461; NCT00048139

An Open Label Study of the Effect of Intermittent Xeloda in Combination With Irinotecan on Treatment Response in Patients With Advanced and/or Metastatic Colorectal Cancer

3066K1-3311; NCT00631371

Phase 3b, Randomized, Open-Label Study of Bevacizumab + Temsirolimus ) vs. Bevacizumab + Interferon-Alfa as First-Line Treatment in Subjects With Advanced Renal Cell Carcinoma

CC-5013-MM-017; NCT00555100

A Multicenter, Phase I Study to Determine the Maximum Tolerated Dose, Safety, Pharmacokinetics and Efficacy of Lenalidomide With and Without Dexamethasone in Japanese Subjects With Previously Treated Multiple Myeloma

SCRI UNKPRI 19, AVF 3830s; NCT00360360

A Phase II Study of Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Patients With Carcinoma of Unknown Primary Site